TLR-2 Recognizes Propionibacterium acnes CAMP Factor 1 from Highly Inflammatory Strains
…, G Ollagnier, P Morand, N Désiré, S Sayon… - PloS one, 2016 - journals.plos.org
Background Propionibacterium acnes (P. acnes) is an anaerobic, Gram-positive bacteria
encountered in inflammatory acne lesions, particularly in the pilosebaceous follicle. P. acnes …
encountered in inflammatory acne lesions, particularly in the pilosebaceous follicle. P. acnes …
Spike gene evolution and immune escape mutations in patients with mild or moderate forms of COVID-19 and treated with monoclonal antibodies therapies
A Jary, S Marot, A Faycal, S Leon, S Sayon, K Zafilaza… - Viruses, 2022 - mdpi.com
We explored the molecular evolution of the spike gene after the administration of anti-spike
monoclonal antibodies in patients with mild or moderate forms of COVID-19. Four out of the …
monoclonal antibodies in patients with mild or moderate forms of COVID-19. Four out of the …
Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo
…, F Simon, I Malet, C Alloui, S Sayon… - Antimicrobial agents …, 2010 - Am Soc Microbiol
Integrase (IN), the HIV-1 enzyme responsible for the integration of the viral genome into the
chromosomes of infected cells, is the target of the recently approved antiviral raltegravir (RAL…
chromosomes of infected cells, is the target of the recently approved antiviral raltegravir (RAL…
Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals
…, I Malet, M Binka, S Boukobza, M Wirden, S Sayon… - Aids, 2010 - journals.lww.com
Background: The HIV-1 Vif protein counteracts the antiviral activity of the cytidine deaminases
APOBEC3G and APOBEC3F. Natural variation in Vif may result in reduced efficacy …
APOBEC3G and APOBEC3F. Natural variation in Vif may result in reduced efficacy …
[HTML][HTML] Prevalence of cervical HPV infection, sexually transmitted infections and associated antimicrobial resistance in women attending cervical cancer screening in …
…, L Beauvais-Remigereau, S Sayon… - International Journal of …, 2021 - Elsevier
Objectives To assess the prevalence of sexually transmitted infections (STIs), antimicrobial
resistance and cervical lesions among women from Sikasso, Mali. Methods Women infected …
resistance and cervical lesions among women from Sikasso, Mali. Methods Women infected …
The 501Y. V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y. V1 and the historical variants in nasopharyngeal samples from newly diagnosed …
…, V Ferre, S Marot, A Jary, S Sayon… - Journal of …, 2021 - journalofinfection.com
The pandemic of severe-acute-respiratory-syndromecoronavirus-2 (SARS-CoV-2) has
precipitated the most extensive global vaccine development programme in history and has …
precipitated the most extensive global vaccine development programme in history and has …
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure
…, C Soulie, M Wirden, P Flandre, DB Fofana, S Sayon… - Aids, 2012 - journals.lww.com
Background: Recent clinical trials with rilpivirine combined with emtricitabine and tenofovir
revealed that patients failing treatment, frequently, harbored viruses encoding resistance-…
revealed that patients failing treatment, frequently, harbored viruses encoding resistance-…
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml
…, P Flandre, N Valin, S Fourati, S Sayon… - Aids, 2011 - journals.lww.com
Objectives: To compare the level of HIV-1 residual viremia, defined by a viral load below 50
copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (…
copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (…
Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies
…, A Fauchois, E Ghidaoui, S Sayon… - Journal of …, 2023 - hal.sorbonne-universite.fr
High-risk patients, often immunocompromised and not responding to vaccine, continue to
experience severe COVID-19 and death. Monoclonal antibodies (mAbs) were shown effective …
experience severe COVID-19 and death. Monoclonal antibodies (mAbs) were shown effective …
Long-term evolution of humoral immune response after SARS-CoV-2 infection
E Teyssou, K Zafilaza, S Sayon, S Marot… - Clinical Microbiology …, 2022 - Elsevier
Objective We aimed to characterize the evolution of humoral immune response up to 1 year
after SARS-CoV-2 infection in healthcare workers (HCWs) during the first wave of COVID-19 …
after SARS-CoV-2 infection in healthcare workers (HCWs) during the first wave of COVID-19 …